Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization
NCT04080167 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 382
Last updated 2023-11-29
Summary
This project proposes to develop, test and evaluate targeted interventions to improve clinical provider prescribing of and patient adherence to hydroxyurea (HU). Using a stepped-wedge design, The investigators will test two innovative interventions utilizing mobile health to address both patients' and providers' needs: 1) an mHealth application for patients (InCharge Health app) that includes multi-component features to address the memory, motivation, and knowledge barriers to hydroxyurea use, and 2) an mHealth toolbox application for providers (HU Toolbox app) that addresses clinical knowledge barriers in prescribing and monitoring hydroxyurea use. These two interventions will be tested through the following aims:
Aim 1. Improve Patient Adherence to Hydroxyurea: Addressing Memory, Motivation, and Knowledge Barriers to Hydroxyurea Use. Primary hypothesis: The investigators hypothesize that among adolescents and adults with SCD, the adherence to hydroxyurea, as measured by percentage of days covered (PDC), will increase by at least 20% at 24 weeks after receiving the InCharge Health app, compared to their hydroxyurea adherence at baseline.
Sub-aim 1.a. To examine and assess both patient engagement and behaviors related to use of the InCharge Health app, the investigators will evaluate consistent use of the app among enrolled patients, patient satisfaction, and continued use of the app beyond the study period.
Sub-Aim 1.b. To examine the clinical influence of the use of the InCharge Health app on PDC, patients' clinical outcomes, perceived health literacy, health related quality of life, and perceived self-efficacy between baseline and 24 weeks.
Aim 2. Improve Provider Hydroxyurea Awareness, Prescribing and Monitoring Behaviors.
Sub-Aim 2.a. To examine and assess provider engagement and behaviors related to use of the HU Toolbox, the investigators will evaluate consistent use of the app among enrolled providers, providers' satisfaction, and continued use of the app beyond the study period.
Sub-Aim 2.b. To assess the combined effects of the patient and provider mHealth interventions on hydroxyurea and health care utilization, the investigators will examine if the changes in hydroxyurea adherence are enhanced by the use of both provider and patient interventions compared to those not exposed to one or both interventions.
Aim 3. Identify and Evaluate the Barriers and Facilitators to the use of mHealth Interventions.
Conditions
Interventions
- BEHAVIORAL
-
InCharge Health mobile application
The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a "health partner"; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a "health partner", who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been \<4 hours since not documenting the use of hydroxyurea. The "app healthy partner" will be encouraged to message the participant to remind him/her to take the medication.
- BEHAVIORAL
-
HU Toolbox mobile application
The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
Sponsors & Collaborators
-
RTI International
collaborator OTHER -
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
University of Memphis
collaborator OTHER -
St. Jude Children's Research Hospital
lead OTHER
Principal Investigators
-
Jane Hankins, MD · St. Jude Children's Research Hospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 15 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-11-11
- Primary Completion
- 2022-04-06
- Completion
- 2022-08-31
Countries
- United States
Study Locations
More Related Trials
-
Exploring Adherence Monitoring in Sickle Cell Disease
NCT03708731 ·Status: ACTIVE_NOT_RECRUITING
-
Pilot Evaluation of a Motivational Interviewing Intervention Targeting Adherence Behaviors in Youth With Sickle Cell Disease
NCT04877054 ·Status: COMPLETED ·Phase: NA
-
Patient Centered Comprehensive Medication Adherence Management System in Patients With Sickle Cell Disease
NCT02371720 ·Status: COMPLETED ·Phase: NA
-
Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial
NCT03462511 ·Status: COMPLETED ·Phase: NA
-
Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study
NCT04678037 ·Status: COMPLETED ·Phase: NA
-
ElectroNic Hydroxyurea AdhereNCE: A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease
NCT02578017 ·Status: COMPLETED ·Phase: NA
-
Efficacy of a Decision Aid for Hydroxyurea in Sickle Cell Disease
NCT03577691 ·Status: TERMINATED ·Phase: NA
-
Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
NCT02225132 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
SMYLS: A Self-management Program for Youth Living With Sickle Cell Disease
NCT04289311 ·Status: COMPLETED ·Phase: NA
-
Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease
NCT03629678 ·Status: COMPLETED ·Phase: NA
-
Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
NCT00143572 ·Status: COMPLETED ·Phase: PHASE1
-
Mobile-Directly Observed Therapy on Adherence to Hydroxyurea
NCT02844673 ·Status: COMPLETED ·Phase: PHASE2
-
Adherence to Hydroxyurea in Children With Sickle Cell Anemia
NCT00672789 ·Status: COMPLETED ·Phase: NA
-
Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
NCT00000586 ·Status: COMPLETED ·Phase: PHASE3
-
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
NCT02029742 ·Status: COMPLETED ·Phase: NA
-
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
NCT06919224 ·Status: RECRUITING ·Phase: NA
-
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
NCT03263559 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Mobile Technology for Intensive Training in Medication Management
NCT02133560 ·Status: COMPLETED ·Phase: NA
-
Community Health Workers and mHealth for Sickle Cell Disease Care
NCT03648710 ·Status: COMPLETED ·Phase: NA
-
Predictors and Outcomes in Patients With Sickle Cell Disease
NCT03431935 ·Status: COMPLETED
-
Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas
NCT03128515 ·Status: COMPLETED ·Phase: PHASE3
-
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
NCT00532883 ·Status: TERMINATED ·Phase: PHASE2
-
Use of a Mobile-based App for SCD Patients
NCT01833702 ·Status: COMPLETED
-
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
NCT01895361 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Hydroxyurea to Treat Sickle Cell Disease
NCT02868138 ·Status: COMPLETED